Search

Your search keyword '"Jankovic J"' showing total 16 results
Start Over Author "Jankovic J" Journal parkinsonism & related disorders
16 results on '"Jankovic J"'

1. McLeod syndrome: Five new pedigrees with novel mutations

Author

Weaver, J., primary, Sarva, H., additional, Barone, D., additional, Bobker, S., additional, Bushara, K., additional, Hiller, A., additional, Ishii, M., additional, Jankovic, J., additional, Lakhani, S., additional, Niotis, K., additional, Scharre, D.W., additional, Tuite, P., additional, Stutz, A., additional, Westhoff, C.M., additional, and Walker, R.H., additional

Published
2019
Full Text
View/download PDF

2. Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease

Author

Jankovic, J., primary, Goodman, I., additional, Safirstein, B., additional, Schenk, D.B., additional, Kinney, G.G., additional, Koller, M., additional, Ness, D.K., additional, Griffith, S.G., additional, Grundman, M., additional, Soto, J., additional, Ostrowitzki, S., additional, Boess, F.G., additional, Martin-Facklam, M., additional, Quinn, J.F., additional, Issacson, S.H., additional, Jennings, D., additional, Omidvar, O., additional, and Ellenbogen, A., additional

Published
2018
Full Text
View/download PDF

4. Mobility, mood and site of care impact health related quality of life in Parkinson's disease

Author

Nutt, J.G., primary, Siderowf, A.D., additional, Guttman, M., additional, Schmidt, P.N., additional, Zamudio, J.I., additional, Wu, S.S., additional, Okun, M.S., additional, Simuni, T., additional, Parashos, S.A., additional, Dahodwala, N.A., additional, Davis, T.L., additional, Giladi, N., additional, Gurevich, T., additional, Hauser, R.A., additional, Jankovic, J., additional, Lyons, K.E., additional, Marsh, L., additional, Miyasaki, J.M., additional, Morgan, J.C., additional, Santiago, A.J., additional, Tarsy, D., additional, Mari, Z., additional, Malaty, I.A., additional, and Nelson, E.C., additional

Published
2014
Full Text
View/download PDF

5. Continuous in-home monitoring of essential tremor

Author

Pulliam, C.L., primary, Eichenseer, S.R., additional, Goetz, C.G., additional, Waln, O., additional, Hunter, C.B., additional, Jankovic, J., additional, Vaillancourt, D.E., additional, Giuffrida, J.P., additional, and Heldman, D.A., additional

Published
2014
Full Text
View/download PDF

6. 2.300 SAFETY DATA IN A RANDOMIZED CONTROLLED TRIAL OF CONSTANT CURRENT DBS VERSUS LEAD PLACEMENT ALONE FOR PARKINSON'S DISEASE MOTOR FLUCTUATIONS

Author

Tagliati, M., primary, Gallo, B.V., additional, Mandybur, G.T., additional, Arle, J.E., additional, Elias, W.J., additional, Ford, B., additional, Horn, S.S., additional, Hung, S.W., additional, Jankovic, J., additional, Junn,, F.S., additional, Marshall, F.J., additional, Stewart, R.M., additional, Swope, D.M., additional, Verhagen, L., additional, and Okun, M.S., additional

Published
2012
Full Text
View/download PDF

8. P2.113 Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD)

Author

Marks, W., primary, Bartus, R., additional, Siffert, J., additional, Starr, P., additional, Ostrem, J., additional, Stacy, M., additional, Boulis, N., additional, Vitek, J., additional, Verhagen, L., additional, Watts, R., additional, Jankovic, J., additional, Tagliati, M., additional, Stern, M., additional, Nutt, J., additional, Kordower, J., additional, Lozano, A., additional, Kieburtz, K., additional, Davis, C., additional, Bloom, F., additional, and Olanow, C.W., additional

Published
2009
Full Text
View/download PDF

15. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.

Author

Elmer LW, Surmann E, Boroojerdi B, Jankovic J, Elmer, Lawrence W, Surmann, Erwin, Boroojerdi, Babak, and Jankovic, Joseph

Abstract

Purpose: This prospective, open-label extension (SP702; NCT00594165) of a 6-month double-blind, randomized study investigated the long-term safety and tolerability of rotigotine transdermal system in early Parkinson's disease (PD).Methods: Patients with early-stage idiopathic PD received transdermal rotigotine for up to 6 years at optimal dose (up to 16 mg/24h). Adjunctive levodopa was allowed. Primary outcomes included adverse events (AEs) and extent of rotigotine exposure. Other outcomes included time to levodopa, incidence of dyskinesias, and efficacy using the Unified Parkinson's Disease Rating Scale (UPDRS) II+III total score.Results: Of 217 patients entering the open-label study, 47% were still in the study upon closure; 24% withdrew because of AEs and 6% because of lack of efficacy. The median exposure to rotigotine was 1910 days (≈ 5 years, 3 months; range 1-2188 days). Most common AEs were somnolence (23% per patient-year), falls (17%), peripheral edema (14%), nausea (12%), and application site reactions (ASRs; 12%). 3% withdrew because of ASRs. 26% patients did not initiate levodopa; of those who did, fewer than half started levodopa in the first year. Dyskinesias were reported by 25% patients; the majority (83%) reported their first episode after initiating levodopa. Mean UPDRS II+III total scores remained below double-blind baseline for up to 2 years of open-label treatment.Conclusion: This is the longest interventional study of rotigotine conducted to date. Transdermal rotigotine was generally well tolerated for up to 6 years; AEs reported were similar to those observed in shorter studies and led to discontinuation in only 24% patients. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results